The overall evidence for the procedure is “insufficient” at present, but good enough to allow coverage, the agency says.

The data indicate it’s worth a shot to try TEER in many with secondary MR, but clinical judgement is critical.

Some believe that future studies are still needed to tease out whether there are high-risk subgroups who will benefit.

When encountering elderly ACS patients, clinical judgement is important given the risks of bleeding, says Arnold Seto.

There have been three deaths and no serious injuries tied to a problem affecting detection of the pumps, according to Abiomed ...

A true test of durability will take many more years, but if the valve holds up, it’s “potentially a game changer,” say ...

Permanent pacemaker rates were nearly 18% at 30 days but came down as sites gained experience with the new device.

Gi-Byoung Nam, Duk-Woo Park, and C. Michael Gibson weigh edoxaban monotherapy vs dual antithrombotic therapy for patients with AF and stable coronary artery disease.

The most read stories this past month detailed the passing of Dimitrios Karmpaliotis and news on Evoque and COVID-19.

The results suggest minimal health status benefits once TR has dropped by three grades, but further research is needed.

Overall age-adjusted mortality rates have fallen, but the poorest parts of the world aren’t sharing in the benefits.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the ...